TrialMedicine2017

Combination of transcatheter arterial chemoembolization and interrupted dosing sorafenib improves patient survival in early-intermediate stage hepatocellular carcinoma: A post hoc analysis of the START trial.

Teng-Yu Lee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.